ALZNAlzamend Neuro, Inc.

Nasdaq alzamend.com


$ 2.09 $ -0.03 (-1.42 %)    

Monday, 09-Sep-2024 15:59:47 EDT
QQQ $ 455.25 $ 5.77 (1.29 %)
DIA $ 409.08 $ 4.58 (1.13 %)
SPY $ 546.60 $ 6.05 (1.12 %)
TLT $ 99.96 $ 0.43 (0.43 %)
GLD $ 231.58 $ 0.97 (0.42 %)
$ 2.09
$ 2.19
$ 2.07 x 100
-- x --
$ 2.05 - $ 2.19
$ 1.84 - $ 40.04
369,200
na
1.76M
$ 1.07
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-30-2024 04-30-2024 10-K
2 03-25-2024 01-31-2024 10-Q
3 12-15-2023 10-31-2023 10-Q
4 09-13-2023 07-31-2023 10-Q
5 07-27-2023 04-30-2023 10-K
6 03-15-2023 01-31-2023 10-Q
7 12-12-2022 10-31-2022 10-Q
8 09-13-2022 07-31-2022 10-Q
9 07-19-2022 04-30-2022 10-K
10 03-15-2022 01-31-2022 10-Q
11 12-13-2021 10-31-2021 10-Q
12 09-13-2021 07-31-2021 10-Q
13 07-29-2021 04-30-2021 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 nvidia-amd-alzamend-neuro-palo-alto-networks-tesla-why-these-5-stocks-are-on-investors-radars-today

On Monday, major U.S. indices closed in positive territory. The Dow Jones Industrial Average rose 0.6% to finish at 40,896.53.

 alzamend-neuro-stock-jumps-after-post-traumatic-stress-disorder-study-pact-details

Alzamend Neuro stock rises after partnering with Massachusetts General Hospital for a Phase 2 trial of AL001 to treat PTSD. The...

Core News & Articles

ALZN: 248% | Alzamend Neuro Partners With Massachusetts General Hospital For First-of-Its-Kind Phase II Study Of AL001 For PTSD...

 alzamend-neuro-partners-with-massachusetts-general-hospital-for-first-of-its-kind-phase-ii-study-of-al001-for-ptsd-treatment

Harvard Associate Professor Dr. Ovidiu Andronesi To Lead Study Comparing AL001 To Marketed Lithium Carbonate In Human Brain

 alzamend-neuro-partners-with-massachusetts-general-hospital-for-a-phase-ii-clinical-trial-of-al001-a-nextgeneration-lithium-therapeutic-drug-candidate

Harvard University Associate Professor, Dr. Ovidiu Andronesi MD, PhD, will be the principal investigator of the studyHead-to-he...

 alzamend-neuro-regains-compliance-with-nasdaqs-minimum-bid-price-requirement

Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel...

 alzamend-neuro-announces-1-for-10-reverse-stock-split-beginning-with-the-opening-of-trading-on-july-16-2024

Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend" or the "Company"), a clinical-stage biopharmaceutical company fo...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION